Parkinson's Disease Dementia
11
1
2
8
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
9.1%
1 terminated out of 11 trials
88.9%
+2.3% vs benchmark
18%
2 trials in Phase 3/4
50%
4 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 8 completed trials
Clinical Trials (11)
To Assess the Efficacy and Safety of Ceftriaxone in Patients With Mild to Moderate Parkinson's Disease Dementia
Imaging Inflammation in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies
Ambroxol as a Treatment for Parkinson's Disease Dementia
Cerebro Spinal Fluid Collection (CSF)
Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD)
Study Evaluating Intepirdine (RVT-101) on Gait and Balance in Subjects With Dementia
Open-label Study of Nelotanserin in Lewy Body Dementia With Visual Hallucinations or REM Sleep Behavior Disorder
Nilotinib in Cognitively Impaired Parkinson Disease Patients 001
An Observational Study for the Prevalence of Neuropsychiatric Symptom in Parkinson's Disease Dementia
Memantine Versus Placebo in Parkinson's Disease Dementia or Dementia With Lewy Bodies
Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD)